2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 190

An Innovative Pilot Educational Program to Inform Rheumatology Fellows about the Population of the Bronx: Issues Affecting and Resources Available to the Community
Abstract Number: 1982

An Integrative Rheumatoid Arthritis Network for Elucidating Molecular Mechanisms Underlying RA Severity
Abstract Number: 857

An Interactive Rheumatology Curriculum for Interprofessional Teams Using a Novel Mobile App
Abstract Number: 867

An MRI Guided Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission Improved MRI Inflammation but Not Damage Progression – Results from the Imagine-RA Randomized Controlled Trial
Abstract Number: 120

An Orally Available Highly Selective 5-Hydroxytryptamine 2B Receptor Antagonist Ameliorating Pulmonary and Dermal Fibrosis in Preclinical Models of Systemic Sclerosis
Abstract Number: 1790

An Unmet Need for Oral Ulcer Activity in Patients with Behcet’s Disease: A Multi-National Study
Abstract Number: 1797

An Update on Pulmonary Artery Involvement in Behcet’s Syndrome: More Pulmonary Artery Thrombotic Disease and a Better Outcome
Abstract Number: 1295

Anakinra Is More Effective at Reducing Pain from Acute Crystal Induced Arthritis When Compared to Conventional Therapy: A Retrospective Review at a Tertiary Care Center
Abstract Number: 1324

Anakinra Treatment in Refractory Cases of Adult-Onset Still Disease: Case Series
Abstract Number: 922

Anakinra Treatment Prevents Myocardial Mechanical Dysfunction and Inhibits Histologic Evidence of Myocardial Inflammation in the Mouse Model of Kawasaki Disease
Abstract Number: 82

Analysis of Intestinal Microbiome Profile of Patients with Established Rheumatoid Arthritis and Healthy Controls
Abstract Number: 2123

Analysis of Lupus Synovitis Gene Expression Reveals Dysregulation of Pathogenic Pathways Activated within Infiltrating Immune Cells
Abstract Number: 2437

Analysis of Occurrence of Small for Gestational Age Infants in Women with Systemic Lupus Erythematosus
Abstract Number: 522

Analysis of Sequential Development of Pulmonary Lesions in Patients with Rheumatoid Arthritis
Abstract Number: 2461

Analysis of Severe Adverse Drug Reactions to Disease Modifying Drugs in an Inception Rheumatoid Arthritis Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].